-
System-Level Economic Impact of a Combination Influenza-COVID-19 Vaccine vs. Standalone Vaccinations in the United Kingdom
Sep 9, 2025, 16:22 PM -
Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands
Sep 9, 2025, 16:22 PM -
The Use of Dynamic Models in Economic Evaluations in the UK and France
Sep 9, 2025, 16:22 PM -
Exploring the Integration of Artificial Intelligence in Health Economic, Systematic Review, and Evidence Synthesis Methods: A Scoping Review of NICE Technology Appraisal and Assessment Reports
Sep 9, 2025, 16:22 PM -
Trends in Vaccination at Pharmacies by Race Among Medicaid Recipients: A Claims Analysis
Sep 9, 2025, 16:22 PM -
The Use of Real-World Evidence in Health Technology Assessment and the Application of the NICE RWE Framework: A Review of NICE Technology Appraisals
Sep 9, 2025, 16:22 PM -
Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease
Sep 9, 2025, 16:22 PM -
A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal
Sep 9, 2025, 16:22 PM -
Citizens’ Send Messages to Policy Makers Related to Primary Healthcare Practices: First Results From the Implementation of the Patient-Reported Indicator Surveys PaRIS in Greece
Sep 9, 2025, 16:22 PM -
Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study
Sep 9, 2025, 16:22 PM -
Economic Burden Associated With Type 2 Diabetes Mellitus in France: An Update From the National Insurance Claim Database
Sep 9, 2025, 16:22 PM -
Direct Economic Impact of Idiopathic Pulmonary Fibrosis on the Brazilian Private Healthcare System: A Real-World Data Analysis
Sep 9, 2025, 16:22 PM -
Direct and Indirect Economic Burden Due to Chronic Limb-Threatening Ischemia (CLTI) in Germany
Sep 9, 2025, 16:22 PM -
Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products Across Europe
Sep 9, 2025, 16:22 PM -
How Are Clinical Trials for Breast Cancer Treatments Currently Being Designed? A Clinical Trial Database Analysis
Sep 9, 2025, 16:22 PM -
Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom
Sep 9, 2025, 16:22 PM -
Indirect Comparison of Tarlatamab vs. Chemotherapy (CTx) in Patients With Previously Treated, Platinum-Refractory, or Resistant Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Improving Data Quality in Oncology Electronic Health Record (EHR)-Derived Databases for Research and Regulatory Decision Making
Sep 9, 2025, 16:22 PM -
Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in Brazil
Sep 9, 2025, 16:22 PM -
Optimizing PICO Scoping in EU HTA: Lessons From a HTA Coordination Group PICO Exercise in Advanced NSCLC to Inform Future Best Practice
Sep 9, 2025, 16:22 PM
